ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection.
LUXEMBOURG and ZUG, Switzerland, May 19, 2020 /PRNewswire/ -- Covis Pharma B.V. today announced the initiation of a Phase 3 clinical study to assess the safety and efficacy of its asthma drug Alvesco (ciclesonide) in non-hospitalized patients 12 years of age and older with symptomatic COVID-19. Patient recruitment for the multicenter, randomized, double-blind, placebo-controlled study of Alvesco is underway. The study is being initiated after FDA approval of the company's IND filing for Alvesco for the treatment of COVID-19.
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on May 12, informing that applications for COVID-19 infection treatments might be accepted without clinical trial results if a certain degree of their efficacy and safety are confirmed in…
AstraZeneca has been hiving off drug rights left and right in recent years as a quick—but controversial—way to generate cash. With billions in rights sales already in its pocket, the company Tuesday offloaded United States and Canadian rights to once-blockbuster antipsychotic meds Seroquel and Seroquel XR.
The Committee adopted by majority a positive opinion for an initial marketing authorisation application for Stelfonta (tigilanol tiglate), from QBiotics Netherlands B.V., a new product for the treatment of non-resectable, non-metastatic cutaneous and subcutaneous mast cell tumours in dogs. The product was classified as MUMS/limited market.
Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey
PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion